Hansoh conducted a new clinical study to evaluate the efficacy of anti-B7H4 ADC in combination with anti-PD-L1 or anti-VEGF mAbs for treating solid tumors. This marks the 3rd clinical trial for HS-20089 in China.
HS-20089 is a novel B7-H4 targeted ADC with a TOPOi payload (DAR=6), developed by Hansoh and licensed to GSK with an $85 million upfront payment.
 |
| Factors controlling B7-H4 and B7-H4 receptor expression |
The clinical study
This study contains four combination therapy cohorts, each consisting of a dose exploration part and a dose expansion part.
The combination includes Adebrelimab, an anti-PD-L1 monoclonal antibody, either with or without platinum, or Bevacizumab with or without platinum. Adebrelimab was an anti-PD-L1 monoclonal antibody discovered and launched by Hengrui in China as their second anti-PD-(L)1 therapy.
The clinical trial identified as NCT06336707 is expected to enroll a total of 1,048 participants, while the trial registered in China (CTR20241023) showed an enrollment of 208 patients.
Anti-B7H4 ADC
|
Product |
Company |
Combo |
Stage |
Enrollment |
Initiation |
|
AZD8205 |
AstraZeneca |
- |
Phase 1/2 |
248 |
2021.10.18 |
|
HS-20089 |
Hansoh/GSK |
- |
Phase 1 |
177 |
2022.01.05 |
|
- |
Phase 2 |
460 |
2023.12.31 |
||
|
Adebrelimab Bevacizumab |
Phase 1 |
1,048 |
2024.04.08 |
||
|
SGN-B7H4V |
Seagen/Pfizer |
- |
Phase 1 |
430 |
2022.01.12 |
|
XMT-1660 |
Mersana |
- |
Phase 1 |
319 |
2022.08.15 |
|
BG-C9074 |
Beigene |
Tislelizumab |
Phase 1 |
150 |
2024.05.06 |
Last month, we reported that Beigene commenced the first-in-human trial (NCT06233942) of BG-C9074 mono or in combination with anti-PD-1 mAb. BG-C9074 is an ADC that targets B7-H4. It has a DAR of 6 and was developed in collaboration with DualityBio.
Mersana has announced that the XMT-1660 trial's dose escalation phase is currently underway, with an escalated dose of 59 mg/m2. The Maximum Tolerated Dose (MTD) has not yet been determined. Furthermore, they are also enrolling patients in backfill cohorts to optimize the dosage and schedule.
AZD8205 has moved from phase 1 to phase 2 as of 2022 Q2. The results are expected to be available in 2025.
Comments